Clinical trial
A Phase 2 Trial of the Efficacy and Safety of the Interleukin-17A Inhibitor Izokibep (ABY-035) in the Treatment of Non-infectious Intermediate, Posterior or Pan-uveitis (LINNAEA)
NCT04706741 is registered in ClinicalTrials.gov with ACELYRIN Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Trial of the Efficacy and Safety of the Interleukin-17A Inhibitor Izokibep (ABY-035) in the Treatment of Non-infectious Intermediate, Posterior or Pan-uveitis (LINNAEA)
- Lead sponsor
- ACELYRIN Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 6, 2022
- Completion date
- November 14, 2022
- Enrollment
- 7 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.